Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial.

ABSTRACT:

Context

Amyloid-beta peptide (Abeta(42)) has been implicated in the pathogenesis of Alzheimer disease (AD). Tarenflurbil, a selective Abeta(42)-lowering agent, demonstrated encouraging results on cognitive and functional outcomes among mildly affected patients in an earlier phase 2 trial.

Objective

To determine the efficacy, safety, and tolerability of tarenflurbil.

Design, setting, and patients

A multicenter, randomized, double-blind, placebo-controlled trial enrolling patients with mild AD was conducted at 133 trial sites in the United States between February 21, 2005, and April 30, 2008. Concomitant treatment with cholinesterase inhibitors or memantine was permitted.

Intervention

Tarenflurbil, 800 mg, or placebo, administered twice a day.

Main outcome mea

SUBMITTER: Green RC 

PROVIDER: S-EPMC2902875 | biostudies-literature | 2009 Dec

REPOSITORIES: biostudies-literature